Home / Healthcare/ Bayer in frame to win first EU nod for high-precision cancer drug

Bayer in frame to win first EU nod for high-precision cancer drug


Comments / {{hitsCtrl.values.hits}} Views / Tuesday, 30 July 2019 00:10


Reuters: Europe’s drug regulator has recommended approving Bayer’s Vitrakvi, putting the medicine on track to become the first in Europe to tackle tumours with a specific genetic mutation regardless of where in the body the disease started.

The drug is being recommended for adults and children with difficult to treat forms of cancer that are driven by a rare genetic mutation known as NTRK gene fusion, the European Medicines Agency (EMA) said on Friday (bit.ly/2Mi6s5o).

The European Commission has the final word on drug approvals but it generally follows EMA’s recommendation within a couple of months.

The EMA endorsement marks a boost for the German company’s drug development pipeline, which many analysts regard as too thin to make up for an expected decline in revenues from its two pharma bestsellers from about 2024.

The concept of a cancer drug’s use based on genetic growth drivers and not on the tumour’s location in the body received its first regulatory go-ahead in the US in 2017.

 


Share This Article

Facebook Twitter


DISCLAIMER:

1. All comments will be moderated by the Daily FT Web Editor.

2. Comments that are abusive, obscene, incendiary, defamatory or irrelevant will not be published.

3. We may remove hyperlinks within comments.

4. Kindly use a genuine email ID and provide your name.

5. Spamming the comments section under different user names may result in being blacklisted.

COMMENTS

Today's Columnists

Victory over the oppressed

Tuesday, 19 November 2019

The Presidential Election is over and the new President has taken his oaths. Although there were opinions expressed that there can be a second count of preference votes of the candidates other than the first and second, it was an easy victory for Got


The mantra of attracting high-end tourists

Tuesday, 19 November 2019

“Easier said than done!” is what many veterans of the tourism industry say whenever the subject of enticing high spenders to Sri Lanka is debated. That being so, some boutique brands have fetched high prices in the past though the current situati


Adopt high-impact interventions to secure future of antibiotics and rollback the global AMR crisis

Tuesday, 19 November 2019

Antimicrobial resistance (AMR) is a global crisis that threatens the future of our most precious drugs: antibiotics. Across the world, AMR kills an estimated 700,000 people annually, including 230,000 from multi-drug resistant tuberculosis. By 2050,


A child’s guide to MCC Compact Sri Lanka

Monday, 18 November 2019

Intelligent children, unlike some of the adults, are curious, probing and questioning. They do not jump to conclusions until and unless they are convinced of facts that have been presented to them. Asani, a student in the Advanced Level class in a le


Columnists More